New Discovery About GLP-1 Drugs: Beyond Blood Sugar Control to Anti-Inflammation
A growing body of research suggests that GLP-1 drugs, such as Zepbound and Ozempic, do more than control appetite and blood sugar. They may also possess powerful anti-inflammatory properties, potentially improving symptoms of arthritis, Crohn’s disease, colitis, and other inflammatory conditions.
Anti-Inflammatory Effects Independent of Weight Loss
Scientists are working to chart the anti-inflammatory pathways these drugs activate. “Yes, weight loss is important, but it’s by no means the whole story,” says Daniel Drucker, an endocrinologist at the University of Toronto. Patient feedback—reporting improvements in arthritis and colitis after taking the drugs—has motivated researchers to investigate whether GLP-1 drugs modulate the immune system independently of weight reduction.
Calibrating the Immune System, Not Simply Suppressing It
In metabolic diseases such as obesity and diabetes, the immune system becomes overactive in response to high cholesterol, fat, or glucose, leading to harmful chronic inflammation. Traditional anti-inflammatory drugs often come at the cost of weakening the immune system. However, clinical data suggest GLP-1 drugs may strike a balance: instead of merely suppressing immunity, they “calibrate or reset” the immune system to restore normal regulation. Studies have shown that semaglutide can reduce C-reactive protein, a key inflammatory biomarker, by about 40%.
Independent Anti-Inflammatory Mechanisms in the Liver
Drucker’s team found that GLP-1 receptors are present in specific liver cells called liver sinusoidal endothelial cells. Activating these cells with semaglutide independently improved liver disease in mice, reducing liver fat, inflammation, and fibrosis—regardless of weight loss. This process involves a complex cascade of intercellular signals that ultimately leads to liver healing. The findings have garnered attention and confirmed an independent anti-inflammatory pathway of semaglutide in the liver.
Cardiovascular and Other Potential Benefits
Dr. Marc Bonaca, a cardiologist at the University of Colorado Anschutz, notes that the anti-inflammatory effects of GLP-1 drugs are also beneficial for cardiovascular health. In a trial he led, patients with peripheral artery disease who took semaglutide showed significant improvements in walking ability, likely due to anti-inflammatory mechanisms in vascular endothelial muscles. “These are vascular, anti-inflammatory drugs with broad benefits,” Bonaca says. Eli Lilly is currently conducting clinical trials on GLP-1 treatments for Parkinson’s disease, Alzheimer’s disease, and addiction.
Looking Ahead: Disease-Specific Studies Are Crucial
Drucker emphasizes that future research must examine the specific effects of GLP-1 drugs on different inflammatory diseases one by one. While anti-inflammatory properties show strong promise in liver disease, they may have limited impact on other conditions. As more evidence emerges, the way these drugs are used and prescribed could fundamentally change.